Role of Early Serial Renal Transplant Allograft Protocol Biopsies in Living Kidney Transplantations

Setoguchi, Kiyoshi; Hyodo, Yoji; Tsujioka, Hirotaka; Inoue, Minoru; Nirazuka, Asumi; Yoshida, Yuriko; Hasegawa, Kintaro; Yasuda, Yuka; Osaka, Akiyoshi; Inoe, Yasuyuki; Nakayama, Akinori; Sadaoka, Yuko; Arai, Gaku; Fujii, Akiko; Shirakawa, Hiroki; Takeda, Takeshi; Saito, Kazutaka; Tokumoto, Tadahiko

doi:10.1016/j.transproceed.2021.11.028

Cited by 2 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In patients with preformed HLA-DSAs, 31–50% patients developed subclinical kidney ABMR by 3 months posttransplant and 14–50% at 1-year posttransplant [20 ▪▪ ,21,22,23 ▪ ,24,25]. This augmented incidence of subclinical ABMR is significant both in patients with persistent preformed or resolved preformed HLA-DSAs compared to patients without HLA-DSAs [20 ▪▪ ].…”

Section: Human Leukocyte Antigen-donor-specific Antibodies For Immune...mentioning

confidence: 98%

DSA in solid organ transplantation: is it a matter of specificity, amount, or functional characteristics?

Louis

Lefaucheur

2022

Current Opinion in Organ Transplantation

View full text Add to dashboard Cite

Purpose of reviewThe present review describes the clinical relevance of human leukocyte antigen (HLA) donor-specific antibodies (HLA-DSAs) as biomarkers of alloimmunity and summarizes recent improvements in their characterization that provide insights into immune risk assessment, precision diagnosis, and prognostication in transplantation.Recent findingsRecent studies have addressed the clinical utility of HLA-DSAs as biomarkers for immune risk assessment in pretransplant and peritransplant, diagnosis and treatment evaluation of antibody-mediated rejection, immune monitoring posttransplant, and risk stratification.SummaryHLA-DSAs have proved to be the most advanced immune biomarkers in solid organ transplantation in terms of analytical validity, clinical validity and clinical utility. Recent studies are integrating multiple HLA-DSA characteristics including antibody specificity, HLA class, quantity, immunoglobulin G subclass, and complement-binding capacity to improve risk assessment peritransplant, diagnosis and treatment evaluation of antibody-mediated rejection, immune monitoring posttransplant, and transplant prognosis evaluation. In addition, integration of HLA-DSAs to clinical, functional and histological transplant parameters has further consolidated the utility of HLA-DSAs as robust biomarkers and allows to build new tools for monitoring, precision diagnosis, and risk stratification for individual patients. However, prospective and randomized-controlled studies addressing the clinical benefit and cost-effectiveness of HLA-DSA-based monitoring and patient management strategies are required to demonstrate that the use of HLA-DSAs as biomarkers can improve current clinical practice and transplant outcomes.

show abstract

Section: Human Leukocyte Antigen-donor-specific Antibodies For Immune...mentioning

confidence: 98%

DSA in solid organ transplantation: is it a matter of specificity, amount, or functional characteristics?

Louis

Lefaucheur

2022

Current Opinion in Organ Transplantation

View full text Add to dashboard Cite

show abstract

Quantitative ultrasound for non-invasive evaluation of subclinical rejection in renal transplantation

et al. 2022

View full text Add to dashboard Cite

Role of Early Serial Renal Transplant Allograft Protocol Biopsies in Living Kidney Transplantations

Cited by 2 publications

References 4 publications

DSA in solid organ transplantation: is it a matter of specificity, amount, or functional characteristics?

DSA in solid organ transplantation: is it a matter of specificity, amount, or functional characteristics?

Quantitative ultrasound for non-invasive evaluation of subclinical rejection in renal transplantation

Contact Info

Product

Resources

About